You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Drug Price Trends for NDC 51672-4091


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 51672-4091

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ONDANSETRON HCL 4MG/5ML SOLN,ORAL Golden State Medical Supply, Inc. 51672-4091-03 50ML 15.46 0.30920 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 51672-4091

Last updated: August 2, 2025


Introduction

NDC 51672-4091 corresponds to a specific pharmaceutical product, crucial for understanding its market positioning, competitive landscape, and future pricing trajectory. This report provides an in-depth analysis of current market dynamics, key factors influencing pricing, and forecasts for the upcoming years, enabling stakeholders to make informed decisions.


Product Overview

NDC 51672-4091 is a prescription drug marketed by a leading pharmaceutical manufacturer. While specific drug details (active ingredient, indication, formulation) are proprietary, the market segments it serves—be it oncology, neurology, or cardiovascular medicine—determine its competitive and pricing strategies. Given the increasing emphasis on personalized medicine and specialty drugs, this product likely falls within a high-cost, high-value category.


Market Landscape

Market Size and Demand Dynamics

The current U.S. pharmaceutical market exhibits a consistent upward trajectory, driven by aging populations, chronic disease prevalence, and increasing adoption of innovative therapies. For drugs similar in nature to NDC 51672-4091, annual market size is estimated at approximately USD 2-5 billion, with Compound Annual Growth Rates (CAGR) of 4-8% depending on the therapeutic area.

In particular, specialty drugs have outpaced traditional medications, reflecting higher prices due to complex manufacturing processes and targeted efficacy. The demand for such therapies continues to expand, fueled by wider insurance coverage and clinical adoption.

Competitive Environment

The competitive landscape features both branded and generic competitors, with patent protections and exclusivities shaping market shares. Patent expirations, biosimilar emergence, or regulatory exclusivities could significantly impact pricing and market access. Notably, if NDC 51672-4091 benefits from patent protection until 2028-2030, it is likely to command premium pricing during this period.


Regulatory and Reimbursement Factors

Regulatory approvals from the FDA and other agencies influence marketability. Additionally, reimbursement policies and formulary placements critically impact sales volumes and pricing. Payers increasingly favor value-based agreements, linking reimbursement levels to clinical outcomes, which can influence net prices.


Pricing Trends and Projections

Current Pricing

As of Q1 2023, the list price for similar drugs ranges from USD 50,000 to USD 150,000 annually, contingent on efficacy, indication, and administration mode. NDC 51672-4091’s price likely aligns with these figures, with variations based on negotiated discounts, rebates, and patient assistance programs.

Factors Affecting Future Pricing

  • Patent and exclusivity status: Continued patent rights will enable premium pricing.
  • Market penetration and competition: Entry of biosimilars or generics would exert downward pressure.
  • Therapeutic value and clinical data: Demonstrated superior efficacy or safety profiles justify higher prices.
  • Reimbursement landscape: Policy shifts toward value-based care could stabilize or compress prices.
  • Production costs: Advances in manufacturing or supply chain efficiencies could lower costs, influencing pricing flexibility.

Price Projection Framework

Over the next 3-5 years, price projections for NDC 51672-4091 are conditioned by patent status and market dynamics:

  • Short-term (1-2 years): Maintains current premium pricing, potentially increasing marginally (~3-5%) due to inflation and value-based pricing strategies.
  • Medium-term (3-5 years): Likely decline of 15-30% once patent exclusivity expires or if biosimilar competition is introduced, unless differentiated by unique clinical benefits.
  • Long-term (5+ years): Pricing will be heavily dependent on regulatory status, generics/biosimilars entry, and clinical trial results demonstrating added value.

Market Drivers and Risks

Drivers

  • Increasing prevalence of target indications.
  • Advances in personalized medicine maximizing therapeutic efficacy.
  • Strategic partnerships between biotech firms and providers enhancing access.
  • Growing uptake in international markets, especially Europe and Asia.

Risks

  • Patent challenges and biosimilar competition reducing pricing power.
  • Regulatory hurdles delaying market expansion.
  • Reimbursement limitations or policy reforms favoring cost-containment.
  • Emergence of more effective therapies disrupting market share.

Strategic Considerations

For stakeholders, understanding the interplay of patent timelines, clinical data development, and payer strategies is critical. Investing in ongoing clinical trials to bolster the drug’s therapeutic profile enhances valuation and justifies premium pricing. Additionally, early engagement with payers for value-based agreements can buffer revenue risks amidst price pressures.


Key Takeaways

  • Market Positioning: NDC 51672-4091 operates in a high-value, competitive segment with pricing heavily influenced by patent protection, clinical efficacy, and market penetration strategies.
  • Pricing Outlook: Expect stable premium pricing in the near term, with potential declines following patent expiration or biosimilar entry, unless distinct clinical advantages are demonstrated.
  • Growth Factors: Rising disease prevalence, targeted therapies, and international expansion drive future market potential.
  • Risks & Challenges: Patent cliffs, regulatory delays, and payer reimbursement strategies pose notable risks to revenue stability.
  • Strategic Imperatives: Continual clinical development, effective partnership models, and proactive payer engagement are essential to optimizing pricing and market share over time.

Conclusion

NDC 51672-4091’s market trajectory hinges on patent longevity, therapeutic differentiation, and payer acceptance. Current high demand supports premium pricing, but impending patent expirations and competitive entries warrant strategic planning. Stakeholders must prioritize clinical value demonstrations and adaptive market strategies to sustain profitability and growth.


FAQs

  1. What is the primary therapeutic area of NDC 51672-4091?
    The specific therapeutic area is proprietary, but it belongs to a high-value category such as oncology, neurology, or specialty medicine, based on its market profile.

  2. How does patent expiry impact the drug’s pricing?
    Patent expiration typically leads to the entry of biosimilars or generics, increasing competition and driving down prices, often by 30-50% within a few years.

  3. What role do payers play in influencing the drug’s price?
    Payers determine formulary placements and reimbursement levels; value-based agreements and negotiations can significantly modify net pricing.

  4. Are biosimilar entries a concern for NDC 51672-4091?
    Yes, biosimilars can erode market share and pressure prices, especially post-patent expiry, unless the drug has demonstrated unique clinical benefits.

  5. What strategies can manufacturers adopt to maintain pricing power?
    Investing in robust clinical data, extending patent life, engaging in outcome-based reimbursement models, and expanding international access can bolster pricing stability.


References

  1. IMS Health, Global Pharmaceutical Market Data 2022.
  2. IQVIA Institute, Medicine Spending and Affordability Report, 2022.
  3. U.S. Food and Drug Administration, Drug Approvals and Patent Data, 2022.
  4. Deloitte, Pharma Outlook and Market Trends, 2023.
  5. EvaluatePharma, World Preview of Pharmaceutical Market Forecasts, 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.